SenzaGen Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 33

Employees

  • Stock Symbol
  • SENZA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.67
  • (As of Thursday Closing)

SenzaGen General Information

Description

SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Medicon Village, Building 401
  • Scheelevägen 2
  • 223 81 Lund
  • Sweden
+46 046-275
Primary Industry
Laboratory Services (Healthcare)
Stock Exchange
STO
Corporate Office
  • Medicon Village, Building 401
  • Scheelevägen 2
  • 223 81 Lund
  • Sweden
+46 046-275

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SenzaGen Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.67 $0.68 $0.53 - $0.91 $19.7M 29.5M 21.9K -$0.08

SenzaGen Financials Summary

In Thousands,
USD
TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 18,377 15,410 23,067 17,731
Revenue 5,194 4,692 4,117 1,796
EBITDA (1,934) (1,026) (1,546) (3,162)
Net Income (1,935) (2,079) (2,456) (3,650)
Total Assets 11,143 9,723 11,499 14,785
Total Debt 400 167 116 79
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SenzaGen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SenzaGen‘s full profile, request access.

Request a free trial

SenzaGen Patents

SenzaGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220026411-A1 Analytical methods and arrays for use in the same Pending 03-Jan-2019
EP-3906323-A2 Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method Pending 03-Jan-2019
AU-2020205151-A1 Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method Inactive 03-Jan-2019
CA-3123717-A1 Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method Pending 03-Jan-2019
GB-201715445-D0 Novel cell line and uses thereof Inactive 25-Sep-2017 C12Q1/6876
To view SenzaGen’s complete patent history, request access »

SenzaGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SenzaGen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore SenzaGen‘s full profile, request access.

Request a free trial

SenzaGen Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Toxhub 11-Nov-2022 Consulting Services (B2B)
VitroScreen 02-Nov-2021 Merger/Acquisition Other Commercial Services
To view SenzaGen’s complete acquisitions history, request access »

SenzaGen Subsidiaries (2)

Company Name Industry Location Founded
Toxhub Consulting Services (B2B) Rome, Italy 2020
VitroScreen Other Commercial Services Milan, Italy
To view SenzaGen’s complete subsidiaries history, request access »

SenzaGen FAQs

  • When was SenzaGen founded?

    SenzaGen was founded in 2010.

  • Where is SenzaGen headquartered?

    SenzaGen is headquartered in Lund, Sweden.

  • What is the size of SenzaGen?

    SenzaGen has 33 total employees.

  • What industry is SenzaGen in?

    SenzaGen’s primary industry is Laboratory Services (Healthcare).

  • Is SenzaGen a private or public company?

    SenzaGen is a Public company.

  • What is SenzaGen’s stock symbol?

    The ticker symbol for SenzaGen is SENZA.

  • What is the current stock price of SenzaGen?

    As of 31-Oct-2024 the stock price of SenzaGen is $0.67.

  • What is the current market cap of SenzaGen?

    The current market capitalization of SenzaGen is $19.7M.

  • What is SenzaGen’s current revenue?

    The trailing twelve month revenue for SenzaGen is $5.19M.

  • What is SenzaGen’s annual earnings per share (EPS)?

    SenzaGen’s EPS for 12 months was -$0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »